The classes of diabetes medications that are either weight neutral or cause weight loss in diabetic patients include the sodium-dependent glucose cotransporter proteins-2 (SGLT-2) inhibitors, also known as gliflozins, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors. Consistently, GLP-1 has the most impact on weight loss, followed by SGLT-2, while DPP-4 has a neutral weight loss impact on obese patients (Haddad et al., 2023). An example of a medication from the SGLT-2 class is empagliflozin, which is sold under the trade name Jardiance.
Order this paper